CRISPR Therapeutics AG

NASDAQ Global Market
Back to all articles
Somewhat Bullish +30

CRISPR Therapeutics (CRSP) Short Sellers Have A Lot Riding on Earnings

📉 CRISPR Therapeutics shares are down nearly 8% year-to-date and over 80% from their 2021 all-time highs.

👤 Chief Operating Officer Julianne Bruno resigned earlier in the month, raising red flags for investors.

🐻 Short interest is high at over 20 million shares, representing roughly 25% of the public float.

📅 The company is set to report quarterly earnings on May 14, 2025, which could trigger volatility.

📈 CRISPR has topped earnings estimates for three consecutive quarters despite low market enthusiasm.

💰 Cathie Wood recently sold over $354,000 worth of shares but remains a long-term believer in the technology.

💊 Casgevy, a gene therapy developed with Vertex Pharmaceuticals, shows promise despite a slow rollout.

🛡️ The company maintains a strong balance sheet with sufficient cash to absorb further losses.

📊 CRSP trades at 1.69 times price-to-book, suggesting a deep-value profile relative to growth peers.

💹 Shares are currently trading at less than $39 per share according to the article's analysis.

Bullish Signals
  • The company has topped earnings estimates for three straight quarters, demonstrating consistent operational performance despite market headwinds.
  • CRISPR possesses a strong balance sheet with ample cash on hand to absorb losses and fund future development.
  • Casgevy, the co-developed gene therapy, has demonstrated significant promise in its clinical trajectory.
  • Prominent investor Cathie Wood views the company as a potential recession-resistant name capable of rising in a weaker economic environment.
  • The stock trades at 1.69 times price-to-book, which is indicative of a deep-value stock rather than one requiring explosive growth metrics.
  • With low expectations set by analysts, even modest positive results could lead to a significant relief rally for the share price.
Risk Factors
  • Shares are down close to 8% year-to-date and more than 80% from their 2021 all-time highs, indicating severe investor skepticism.
  • The untimely resignation of COO Julianne Bruno has introduced uncertainty regarding executive stability and operational leadership.
  • There is a lack of needle-moving good updates on existing products, making the company difficult to value for traditional investors.
  • High short interest of over 25% of the float suggests that bears dominate the stock and could continue to exert downward pressure.
  • The rollout of Casgevy has been described as rather lackluster, failing to meet the high hopes surrounding its market entry.
Full Analysis
Shares of CRISPR Therapeutics (CRSP) have struggled significantly, dropping nearly 8% year-to-date and over 80% from their 2021 highs. The gene-editing company faces valuation challenges due to steep losses and a lack of recent major updates on its existing product pipeline. Compounding these issues is the recent resignation of Chief Operating Officer Julianne Bruno, an event that has raised concerns among investors regarding internal stability and leadership continuity. The stock currently exhibits high short interest, with over 20 million shares sold short representing approximately 25% of the public float. This heavy bearish positioning suggests that short-sellers are betting against the company's near-term prospects ahead of its upcoming earnings report scheduled for May 14, 2025. Analysts note that while the company has topped earnings estimates for three consecutive quarters, the high short interest creates a potential environment for significant volatility if results diverge from low expectations. Despite the negative sentiment, prominent investor Cathie Wood maintains a bullish long-term view on gene editing technology. Although she recently trimmed her position by selling over $354,000 worth of shares, she still considers CRSP a potential performer that could outperform during an economic recession. The article highlights the company's strong balance sheet and its co-developed therapy, Casgevy (with Vertex Pharmaceuticals), as key assets that could drive a turnaround despite a lackluster rollout so far. Valuation metrics suggest the stock may be undervalued relative to its growth potential, trading at 1.69 times price-to-book. With low analyst expectations and a deep-value profile, some observers view the current price of less than $39 per share as an opportunity rather than a risk. The consensus is that while the trajectory has been difficult, the combination of innovation, cash reserves, and potential for a short squeeze makes the stock dangerous to short.